Amphastar Pharmaceuticals, Inc.
AMPH
$17.50
-$0.95-5.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -0.71% | 0.99% | 6.20% | 11.83% | 18.80% |
| Total Other Revenue | -- | -- | -101.08% | -97.16% | -92.43% |
| Total Revenue | -1.39% | -1.65% | -0.03% | 1.37% | 8.05% |
| Cost of Revenue | 4.91% | 1.60% | 7.66% | 12.15% | 17.10% |
| Gross Profit | -7.55% | -4.76% | -6.86% | -7.56% | 0.44% |
| SG&A Expenses | 11.78% | 12.89% | 11.22% | 12.62% | 14.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.35% | 5.67% | 8.04% | 12.01% | 15.35% |
| Operating Income | -28.18% | -20.41% | -19.24% | -20.97% | -7.97% |
| Income Before Tax | -40.48% | -34.66% | -27.09% | -19.73% | -6.06% |
| Income Tax Expenses | -24.22% | -13.96% | -15.18% | -22.73% | 6.56% |
| Earnings from Continuing Operations | -44.06% | -38.51% | -29.22% | -19.10% | -8.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.06% | -38.51% | -29.22% | -19.10% | -8.44% |
| EBIT | -28.18% | -20.41% | -19.24% | -20.97% | -7.97% |
| EBITDA | -20.55% | -14.78% | -14.17% | -15.89% | -3.04% |
| EPS Basic | -41.69% | -36.34% | -27.66% | -18.10% | -8.46% |
| Normalized Basic EPS | -24.00% | -19.58% | -12.46% | -18.66% | -6.07% |
| EPS Diluted | -39.84% | -33.65% | -24.93% | -14.98% | -4.84% |
| Normalized Diluted EPS | -21.25% | -16.12% | -8.99% | -15.50% | -2.55% |
| Average Basic Shares Outstanding | -4.40% | -3.48% | -2.40% | -1.34% | -0.07% |
| Average Diluted Shares Outstanding | -7.65% | -7.38% | -6.16% | -5.10% | -3.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |